HBPCF - Helix BioPharma appoints Jacek Antas as CEO
- Helix BioPharma ( OTCPK:HBPCF ) said Thursday Jacek Antas has been appointed as CEO to replace Artur Gabor with immediate effect.
- Gabor resigned as CEO and director.
- Antas has been on the board since April and has over 25 years of experience in the financial services industry.
For further details see:
Helix BioPharma appoints Jacek Antas as CEO